Redox-reactive autoantibodies in Alzheimer's patients' cerebrospinal fluids: Preliminary studies

Autoimmunity

Volumn 40, Issue 5, 2007, Pages 390-396

  McIntyre, John A ^a   Chapman, Joab ^b   Shavit, E Efrat ^b   Hamilton, Ronald L ^c   DeKosky, Steven T ^c  

^a St Francis Hospital   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Brain; Dementia; ERK1 2 phosphorylation; Oxidation; Reduction; Synaptosome

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; AUTOPSY; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN TISSUE; CELL DAMAGE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; NERVOUS TISSUE; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RAT; SYNAPTOSOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIBODIES, ANTIPHOSPHOLIPID; APOPTOSIS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; OXIDATION-REDUCTION;

EID: 34447283094     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930701421020     Document Type: Article

References (43)

1. McIntyre, JA, Wagenknecht, DR and Faulk, WP (2006) Redox-reactive antibodies: Detection and physiological relevance. Autoimmun Rev, 5, pp. 76-83.
2. Cabiedes, J., Cabal, AR and Alarcon-Segovia, D. (1998) Hidden antiphospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers, or phospholipase treatments. Eur J Immunol, 28, pp. 2108-2114.
3. Lorber, M., George, J. and Shoenfeld, Y. (1996) Hidden autoantibodies. Autoantibodies, pp. 357-363. Elsevier Science BV, Amsterdam
4. Tomer, Y. and Shoenfeld, Y. (1988) The significance of natural autoantibodies. Immunol Invest, 17, pp. 389-424.
5. McIntyre, JA, Wagenknecht, DR and Faulk, WP (2005) Autoantibodies unmasked by redox reactions. J Autoimmun, 24, pp. 311-317.
6. McIntyre, JA (2004) The appearance and disappearance of antiphospholipid antibodies subsequent to oxidation-reduction reactions. Thromb Res, 114, pp. 579-587.
7. McIntyre, JA, Wagenknecht, DR and Faulk, WP (2007) Redox-reactive autoantibodies. Autoantibodies, pp. 47-53. Elsevier, Amsterdam
8. Katzav, A., Litvinjuk, Y., Pick, CG, Blank, M., Shoenfeld, Y., Sirota, P. and Chapman, J. (2006) Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav Brain Res, 169, pp. 289-293.
9. Shoenfeld, Y., Nahum, A., Korczyn, AD, Dano, M., Rabinowitz, R., Beilin, O., Pick, CG, Leider-Trejo, L., Kalashnikova, L., Blank, M. and Chapman, J. (2003) Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus, 12, pp. 436-442.
10. Ziporen, L., Shoenfeld, Y., Levy, Y. and Korczyn, AD (1997) Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest, 100, pp. 613-615.
11. Ischiropoulos, H. and Beckman, JS (2003) Oxidative stress and nitration in neurodegeneration: Cause, effect, or association?. J Clin Invest, 111, pp. 163-169.
12. Smith, MA, Harris, PL Richey, Sayre, LM, Sayre, LM, Beckman, JS and Perry, G. (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci, 17, pp. 2653-2657.
13. Tohgi, H., Abe, T., Yamazaki, K., Murata, T., Ishizaki, E. and Isobe, C. (1999) Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett, 269, pp. 52-54.
14. Cuajungco, MP, Faget, KY, Xudong, H., Tanzi, RE and Bush, AI (2000) Metal chelation as a potential therapy for Alzheimer's disease. Ann NY Acad Sci, 920, pp. 292-304.
15. Huang, X., Moir, RD, Tanzi, RE, Bush, AI and Rogers, JT (2004) Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann NY Acad Sci, 1012, pp. 153-163.
16. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology, 34, pp. 939-944.
17. Hamilton, RL (2000) Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol, 10, pp. 378-384.
18. Mirra, SS, Heyman, A., McKeel, D., Sumi, SM, Crain, BJ, Brownlee, LM, Vogel, FS, Hughes, JP, vanBelle, G. and Berg, L. (1991) The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology, 41, pp. 479-486.
19. Anon (1997) The National Institute on Aging and Regan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease: Consensus Recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging, 18:4, pp. S1-S2.
20. Wagenknecht, DR, Becker, DG, LeFor, WM and McIntyre, JA (1999) Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation, 68, pp. 241-246.
21. Shavit, E. and Chapman, J. (2005) Antiphospholipid antibodies activate ERK and depolarize brain synaptosomes. Immunobiology, 209, p. 40.
22. Sokol, DK, Wagenknecht, DR and McIntyre, JA (2004) Testing for antiphospholipid antibody (aPL) specificities in retrospective "normal" cerebral spinal fluid (CSF). Clin Dev Immunol, 11, pp. 7-12.
23. Ehrlich, P. Das sauerstufbudurfnis des organismus. Eine Farbenanalytische Studie, Hirschwald, Berlin
24. Silverstein, AM (2001) Autoimmunity versus horror autotoxicus: The struggle for recognition. Nat Immunol, 2, pp. 279-281.
25. Gallo, P., Sivieri, S., Ferrarini, AM, Giometto, B., Ruffitti, A., Ritter, E., Chizzolini, C. and Tavolato, B. (1994) Cerebrovascular and neurological disorders associated with antiphospholipid antibodies in CSF and serum. J Neurol Sci, 122:1, pp. 97-101.
26. Knopf, PM, Harling-Berg, CJ, Cserr, HF, Basu, D., Sirulnick, EJ, Nolan, SC, Park, JT, Keir, G., Thompson, EJ and Hickey, WF (1998) Antigen-dependent intrathecal antibody synthesis in the normal rat brain: Tissue entry and local retention of antigen-specific B cells. J Immunol, 161, pp. 692-701.
27. Lai, N-S and Lan, J-L (2000) Evaluation of cerebrospinal anticardiolipin antibodies in lupus patients with neuropsychiatric manifestations. Lupus, 9, pp. 353-357.
28. Leonardi, A., Gandolfo, C., Caponnetto, L., Arata, L. and Vecchia, R. (1985) The integrity of the blood-brain barrier in Alzheimer's type and multi-infarct dementia evaluated by the study of albumin and IgG in serum and cerebrospinal fluid. J Neurol Sci, 67, pp. 253-261.
29. Lawson, LJ, Perry, VH, Dri, P. and Gorden, S. (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience, 39, pp. 151-170.
30. Morgan, BP and Gasque, P. (1996) Expression of complement in the brain: Role in health and disease. Immunol Today, 17, pp. 445-493.
31. D'Andrea, MR (2005) Add Alzheimer's disease to the list of autoimmune diseases. Med Hypotheses, 64, pp. 458-463.
32. D'Andrea, MR (2003) Evidence linking neuronal cell death to autoimmunity in Alzheimer's disease. Brain Res., 982, pp. 9-30.
33. Dimitrov, JD, Ivanovska, ND, Lacroix-Desmazes, S., Doltchinkova, VR, Kaveri, SV and Vassilev, TL (2006) Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. J Biol Chem., 281, pp. 439-446.
34. Bozic, B., Cucnik, S., Kveder, T. and Rozman, B. (2006) Changes in avidity and specificity if IgG during electro-oxidation. Relevance of binding of antibodies to B2-GPI. Autoimmun Rev, 6, pp. 28-32.
35. Adams, JP and Sweatt, JD (2002) Molecular psychology: Roles for the ERK MAP Kinase cascade in memory. Ann Rev Pharmacol Toxicol., 42, pp. 135-163.
36. Cheung, EC and Slack, RS (2004) Emerging role for ERK as a key regulator of neuronal apoptosis. Science STKE., 251, pp. 1-4.
37. Colucci-D'Amato, L., Perrone-Capano, C. and diPorzio, U. (2003) Chronic activation of ERK and neurodegenerative diseases. BioEssays, 25, pp. 1085-1095.
38. Hindley, A. and Kolch, W. (2002) Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of RAF kinases. J Cell Sci., 115, pp. 1575-1581.
39. Selcher, JC, Weeber, EJ, Christia, J., Nekrasova, T., Landreth, GE and Sweatt, JD (2006) A role for ERK MAP Kinase in physiologic temporal integration in hippocampal area CA1. Learn Mem, 10, pp. 26-39.
40. Winder, DG, Martin, KC, Muzzio, IA, Rohrer, D., Chruscinski, A., Kobilka, B. and Kandel, ER (1999) ERK plays a regulatory role in induction of LTP by theta frequency stimulation and its modulation by B-adrenergic receptors. Neuron, 24, pp. 715-726.
41. Zhao, M., Adams, JP and Dudek, SM (2005) Pattern-dependent role of NMDA receptors in action potential generation: Consequences on extracellular signal-regulated kinase activation. J Neurosci., 25, pp. 7032-7039.
42. Chapman, J., Cohen-Armon, M., Shoenfeld, Y. and Korczyn, AD (1999) Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus, 8, pp. 127-133.
43. DeKosky, ST and Marek, K. (2003) Looking backward to move forward: Early detection of neurodegenerative disorders. Science, 302, pp. 830-834.